Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
86.03
+3.02 (3.64%)
At close: Nov 6, 2026, 4:00 PM EST
88.00
+1.97 (2.29%)
After-hours: Nov 6, 2026, 7:30 PM EST

Dianthus Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2.722.046.242.836.421.48
Revenue Growth
-11.70%-67.35%120.63%-55.96%334.76%-
Gross Profit
2.722.046.242.836.421.48
Selling, General & Admin
50.0134.3324.9918.166.741.96
Research & Development
188.73145.6483.1132.8429.3812.61
Operating Expenses
238.75179.97108.15136.1214.56
Operating Income
-236.03-177.93-101.86-48.17-29.71-13.09
Interest & Investment Income
26.619.9611.354.761.150
Currency Exchange Gain (Loss)
-0.05-0.06-0.06-0.090.14-0.03
Other Non Operating Income (Expenses)
-1.35-0.97-0.55-0.06-0.05-
EBT Excluding Unusual Items
-210.82-169.01-91.14-43.56-28.48-13.11
Gain (Loss) on Sale of Investments
8.696.676.17---
Pretax Income
-202.12-162.34-84.97-43.56-28.48-13.11
Net Income
-202.12-162.34-84.97-43.56-28.48-13.11
Net Income to Common
-202.12-162.34-84.97-43.56-28.48-13.11
Net Income Growth
------
Shares Outstanding (Basic)
523933514
Shares Outstanding (Diluted)
523933514
Shares Change
42.60%15.92%546.44%489.48%-78.17%-
EPS (Basic)
-3.91-4.20-2.55-8.45-32.57-3.27
EPS (Diluted)
-3.91-4.20-2.55-8.45-32.57-3.27
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-175.85-129.27-78.29-36.97-29.21-9.94
Free Cash Flow Per Share
-3.41-3.35-2.35-7.17-33.41-2.48
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-8683.89%-8739.34%-1633.75%-1704.67%-462.91%-886.59%
Profit Margin
-7436.50%-7973.33%-1362.78%-1541.22%-443.76%-888.14%
Free Cash Flow Margin
-6469.87%-6349.36%-1255.57%-1308.24%-455.18%-673.24%
EBITDA
-235.9-177.82-101.77-48.11-29.68-
D&A For EBITDA
0.130.110.10.070.03-
EBIT
-236.03-177.93-101.86-48.17-29.71-13.09
Revenue as Reported
2.042.046.242.83--
SEC Filings: 10-K · 10-Q